Skip to content

Rigel Pharmaceuticals RIGL Contract Liabilities

Discontinued — last reported Q3 '20

Contract Liabilities at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$75.75M-46.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$11.78M
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$3.6M

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Rigel Pharmaceuticals’s 10-Q, filed November 5, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.